0.76
price down icon5.01%   -0.0401
after-market Dopo l'orario di chiusura: .76
loading

Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie

pulisher
03:23 AM

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa

03:23 AM
pulisher
10:59 AM

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener

10:59 AM
pulisher
10:52 AM

Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks

10:52 AM
pulisher
09:17 AM

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TipRanks

09:17 AM
pulisher
07:14 AM

Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India

07:14 AM
pulisher
Mar 30, 2025

HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - NewsBreak: Local News & Alerts

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone flagging following CRL - The Pharma Letter

Mar 28, 2025
pulisher
Mar 28, 2025

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma says FDA declined to approve heart disorder therapy - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - MarketScreener

Mar 28, 2025
pulisher
Mar 21, 2025

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

HC Wainwright Brokers Decrease Earnings Estimates for MIST - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Milestone Pharmaceuticals to present clinical data on etripamil - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Breakthrough PSVT Treatment Data: Etripamil Proves Effective for Multiple Episodes - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Jones Financial Companies Lllp Raises Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

HC Wainwright Has Negative Outlook of MIST FY2028 Earnings - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Milestone Pharmaceuticals sets annual meeting date - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Milestone Pharmaceuticals sets annual meeting date By Investing.com - Investing.com UK

Mar 19, 2025
pulisher
Mar 19, 2025

PDUFA Date Nearing for New PSVT Drug - Streetwise Reports

Mar 19, 2025
pulisher
Mar 19, 2025

Milestone Pharma Expands Sale Agreement, Increases Offering By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 18, 2025

SEC Form 424B5 filed by Milestone Pharmaceuticals Inc. - Quantisnow

Mar 18, 2025
pulisher
Mar 18, 2025

Milestone Pharmaceuticals enters open market sale agreement with Jefferies -March 18, 2025 at 05:51 pm EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Milestone Pharma Expands Sale Agreement, Increases Offering - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Milestone Pharmaceuticals: Buy Rating Backed by Promising FDA Approval and Market Expansion Prospects - TipRanks

Mar 17, 2025
pulisher
Mar 14, 2025

Optimistic Buy Rating for Milestone Pharmaceuticals Driven by Strategic Plans and Financial Strength - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Milestone Pharmaceuticals Eyes FDA Approval for CARDAMYST - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Milestone Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post

Mar 13, 2025
pulisher
Mar 13, 2025

Milestone Pharmaceuticals Awaits FDA Decision on CARDAMYST, Prepares for Mid-2025 Launch - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Milestone Pharmaceuticals Inc Full Year Loss Decreases, But Misses Estimates - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Milestone Pharmaceuticals Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Milestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

3 Reasons GNK is Risky and 1 Stock to Buy Instead - The Globe and Mail

Mar 13, 2025
pulisher
Mar 10, 2025

Sun Pharma to acquire Checkpoint Therapeutics for $355 million in cash and milestone payments - CNBCTV18

Mar 10, 2025
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Capitalizzazione:     |  Volume (24 ore):